S&P Futures
4,141.75 +9.50 (+0.23%) Dow Futures
34,085.00 -63.00 (-0.18%) Nasdaq Futures
12,517.25 +103.00 (+0.83%) Russell 2000 Futures
1,966.60 -1.80 (-0.09%) Crude Oil
76.93 +0.52 (+0.68%) Gold
1,967.20 +24.40 (+1.26%)
Gain Therapeutics, Inc. (GANX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.9600 |
| Open | 3.9809 |
| Bid | 3.4700 x 1300 |
| Ask | 5.9700 x 900 |
| Day's Range | 3.8287 - 4.0550 |
| 52 Week Range | 2.3300 - 6.7000 |
| Volume | |
| Avg. Volume | 38,325 |
| Market Cap | 47.177M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2340 |
| Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GANX
Related Research
- Gain Therapeutics, Inc.Daily – Vickers Top Insider Picks for 06/28/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moat7 months agoArgus Research
- ACCESSWIRE
Sidoti's January Micro-Cap Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.
- GlobeNewswire
Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET. A webcast of the presentation
- Zacks
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
